Trial Profile
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 13 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.
- 13 Apr 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2019.
- 13 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.